Disitamab Vedotin (RC48) (CAS: 2136633-23-1)
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) designed for targeted cancer treatment. It consists of a humanized monoclonal antibody targeting the HER2 protein, linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor.
Key Features:
- Targeted Therapy: The antibody binds specifically to HER2-expressing cancer cells, directing the cytotoxic agent precisely to the tumor.
- Cytotoxic Payload: MMAE disrupts microtubule function, leading to cell cycle arrest and cancer cell death.
- Enhanced Efficacy: This ADC delivers higher concentrations of the cytotoxic drug to the tumor, improving effectiveness while minimizing systemic toxicity.
Applications:
- Advanced Gastric Cancer: Approved in China for HER2-overexpressing locally advanced or metastatic gastric cancer patients who have received at least two prior chemotherapy regimens.
- HER2-Positive Urothelial Carcinoma: Designed for HER2-positive locally advanced or metastatic urothelial carcinoma patients after platinum-based chemotherapy.
Handling and Storage:
- Storage: Store at -20°C, away from light and moisture.
- Handling: Use standard laboratory precautions when handling this reagent.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.